Skip to main content

Perspective Therapeutics, Inc.

CATX
Exchange
NYSE
Industry
Pharmaceutical Preparations
SEC CIK
0000728387

In the last 90 days, Perspective Therapeutics, Inc. insiders filed 0 open-market purchases and 5 sales; 131 institutions reported holding it in 13F filings for Q2 2026, worth $297.6M in total; no superinvestor holds it.

Q3 2023 vs. Q2 2023

How the institutions holding Perspective Therapeutics, Inc. changed between Q2 2023 and Q3 2023.

All holders in Q3 2023All holders in Q2 2023

13F holders of CATX: Q2 2023 compared with Q3 2023
MeasureQ2 2023Of which not filed for Q3 2023Q3 2023Change
Holders501490
Shares33.0M75.0K36.5M+3.62M (+11.0%)
Value$22.0M$50.1K$9.99M−$12.0M (−54.5%)

1 institution that held it in Q2 2023 haven't filed for Q3 2023 yet. Not filing isn't selling, so the changes leave them out.

New holders (4)

Institutions that held Perspective Therapeutics, Inc. at the end of Q3 2023 but not at the end of Q2 2023.

Institutions new to CATX in Q3 2023
InstitutionSharesValue% of portfolio
HRT Financial LP102,708$28.0K0.00%
Goldman Sachs Group Inc13,373$3.66K0.00%
Virtu Financial LLC12,729$3.00K0.00%
JPMorgan Chase & Co330$900.00%

Sold out (4)

Institutions that held Perspective Therapeutics, Inc. at the end of Q2 2023 and filed for Q3 2023 without it.

Institutions that sold out of CATX in Q3 2023
InstitutionShares, Q2 2023Value, Q2 2023
Portland Investment Counsel Inc.1,034,100$683.0K
Citadel Advisors LLC166,779$111.4K
Cerity Partners LLC40,000$26.7K
Advisor Group Holdings, Inc.100$63

Not filed for Q3 2023 yet (1)

Institutions that held Perspective Therapeutics, Inc. at the end of Q2 2023 and haven't filed a 13F for Q3 2023. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding CATX in Q2 2023 that haven't filed for Q3 2023
InstitutionShares, Q2 2023Value, Q2 2023
BerganKDV Wealth Management, LLC75,000$50.1K